FIL Ltd lowered its holdings in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 9.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,134 shares of the biotechnology company’s stock after selling 8,084 shares during the quarter. FIL Ltd’s holdings in Spark Therapeutics were worth $5,270,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ONCE. Rockefeller Capital Management L.P. bought a new position in shares of Spark Therapeutics during the 1st quarter valued at $23,940,000. Pinnacle Associates Ltd. bought a new position in shares of Spark Therapeutics during the 1st quarter valued at $15,611,000. OppenheimerFunds Inc. bought a new position in shares of Spark Therapeutics during the 4th quarter valued at $11,249,000. Macquarie Group Ltd. bought a new position in shares of Spark Therapeutics during the 4th quarter valued at $9,012,000. Finally, Spark Investment Management LLC bought a new position in shares of Spark Therapeutics during the 4th quarter valued at $8,833,000.

Spark Therapeutics opened at $76.09 on Wednesday, Marketbeat.com reports. Spark Therapeutics Inc has a 1 year low of $41.06 and a 1 year high of $91.75. The firm has a market capitalization of $2.84 billion, a P/E ratio of -9.97 and a beta of 2.53.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.80). The company had revenue of $15.68 million during the quarter, compared to analyst estimates of $51.55 million. Spark Therapeutics had a negative return on equity of 51.76% and a negative net margin of 935.38%. The business’s revenue for the quarter was up 1134.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.70) earnings per share. equities analysts anticipate that Spark Therapeutics Inc will post -3.43 earnings per share for the current fiscal year.

A number of research analysts have recently weighed in on ONCE shares. Cantor Fitzgerald set a $100.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 20th. JPMorgan Chase & Co. downgraded shares of Spark Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $62.00 to $60.00 in a report on Wednesday, February 14th. Royal Bank of Canada raised their price target on shares of Spark Therapeutics to $75.00 and gave the company an “outperform” rating in a report on Wednesday, May 9th. Leerink Swann restated a “market perform” rating and set a $55.00 price target on shares of Spark Therapeutics in a report on Monday, May 7th. Finally, Mizuho restated a “buy” rating and set a $79.00 price target on shares of Spark Therapeutics in a report on Wednesday, February 21st. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $76.10.

In other Spark Therapeutics news, COO John Furey sold 13,277 shares of the firm’s stock in a transaction on Wednesday, April 18th. The shares were sold at an average price of $82.52, for a total value of $1,095,618.04. Following the sale, the chief operating officer now directly owns 2,277 shares in the company, valued at approximately $187,898.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 40,000 shares of company stock worth $3,200,466 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Spark Therapeutics Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.